Mogamulizumab

New Drug Approvals

 

Immunoglobulin G1, anti-(CC chemokine receptor CCR4) (human-mouse monoclonal
KW-0761 heavy chain), disulfide with human-mouse monoclonal KW-0761 κ-chain,
dimer

Immunoglobulin G1, anti-(human C-C chemokine receptor type 4 (CCR4, K5-5,
CD194)); humanized mouse monoclonal KW-0761 γ1 heavy chain (222-219′)-disulfide
with humanized mouse monoclonal KW-0761 κ light chain, dimer (228-228”:231-231”)-
bisdisulfide
MOLECULAR FORMULA C6520H10072N1736O2020S42 (peptide)
MOLECULAR WEIGHT 146.44 kDa (peptide)

SPONSOR Kyowa Hakko Kirin Co., Ltd.
CODE DESIGNATION KW-0761, KM8761
CAS REGISTRY NUMBER 1159266-37-1

THERAPEUTIC CLAIM Antineoplastic

http://www.ama-assn.org/resources/doc/usan/mogamulizumab.pdf  for structure

Mogamulizumab (USAN; trade name Poteligeo) is a humanized monoclonal antibody targeting CC chemokine receptor 4(CCR4). It has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma.[1]

Mogamulizumab was developed by Kyowa Hakko Kirin Co., Ltd.[2]

T-cell neoplasms, such as adult T-cell leukemia/lymphoma (ATL) and peripheral T-cell lymphoma, are particularly aggressive and, despite novel combination chemotherapy regimens, still have extremely…

View original post 1,396 more words

Advertisements

About luciavazine

PHARMA PROFESSIONAL, ITALY
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s